As many as 70 percent of women with the most common form of breast cancer may be able to skip chemotherapy, based on their score on a genetic test, researchers said Sunday. Patients, aged 18 to 75, were randomly assigned to receive chemotherapy followed by hormonal therapy or hormone therapy alone. Among women younger than 50, outcomes were similar when gene test scores were 15 or lower. Among younger women with scores 16 to 25, outcomes were slightly better in the chemotherapy group. “We are de-escalating toxic therapy.”According to first author Joseph Sparano of Montefiore Medical Center in Bronx, New York, “any woman with early stage breast cancer 75 or younger should have the test and discuss the results” with her doctor.

Source: Punch June 03, 2018 12:56 UTC